Cryptococcosis
- Overview
- Epidemiology
- Pathophysiology
- Clinical Presentation
- Cryptococcal Meningitis
- Pulmonary Cryptococcosis
- Diagnosis
- Treatment
- Complications
- Prognosis
- Prevention
- References
- Featured Videos
Overview
Cryptococcosis is a life-threatening invasive fungal infection caused primarily by two encapsulated basidiomycete yeast species: Cryptococcus neoformans and Cryptococcus gattii. C. neoformans comprises two varieties — var. grubii (serotype A, accounting for approximately 95% of clinical isolates globally) and var. neoformans (serotype D). C. gattii has been reclassified into several molecular types now recognized as distinct species, including C. deuterogattii (VGIIa/VGIIb, responsible for the Vancouver Island outbreak) and C. bacillisporus (VGIII), among others; serotypes B and C fall under this species complex.
The defining virulence factor of Cryptococcus is its large polysaccharide capsule, composed predominantly of glucuronoxylomannan (GXM) and galactoxylomannan (GalXM). The capsule is profoundly anti-phagocytic, inhibits complement activation, suppresses T-cell proliferation, induces interleukin-10 (IL-10) secretion, and directly interferes with antigen presentation — effectively cloaking the organism from innate and adaptive immune recognition. A second key virulence mechanism is melanin production in the cell wall, catalyzed by the enzyme laccase, which uses dopamine as a substrate in the central nervous system. Melanin scavenges reactive oxygen species produced by phagocytes, contributing directly to the organism's remarkable neurotropism and survival within the CNS.
The environmental reservoir of C. neoformans is ubiquitous worldwide: dried pigeon and other bird droppings provide the ideal alkaline, nitrogen-rich substrate for yeast proliferation. Desiccated yeast cells and basidiospores (1–2 µm in diameter) become airborne and are inhaled as the primary route of infection. C. gattii is associated with decaying wood hollows and bark of certain tree species, originally eucalyptus in tropical and subtropical regions. The global burden of cryptococcal disease is staggering: estimates place the annual incidence of cryptococcal meningitis at approximately 223,100 cases per year, resulting in roughly 181,100 deaths — the vast majority occurring in sub-Saharan Africa among people living with advanced HIV/AIDS.
Epidemiology
Cryptococcus neoformans infection is distributed worldwide and is overwhelmingly an opportunistic pathogen in the setting of impaired cellular immunity. The strongest and most prevalent risk factor is advanced HIV/AIDS, particularly with CD4 T-cell counts below 100 cells/µL. In sub-Saharan Africa, cryptococcal meningitis accounts for an estimated 15–20% of all AIDS-related deaths, making it the single most common cause of adult meningitis in many high-prevalence countries — exceeding bacterial meningitis and tuberculous meningitis in some settings. The Southern and Eastern African regions carry the highest absolute burden.
Beyond HIV, populations at elevated risk include solid organ transplant recipients (particularly those receiving calcineurin inhibitors such as tacrolimus and cyclosporine, which impair T-cell–mediated immunity that is central to cryptococcal containment), patients on prolonged high-dose corticosteroids, those receiving anti-CD20 monoclonal antibodies (rituximab) or other lymphocyte-depleting biologics, individuals with sarcoidosis (which causes granulomatous impairment of cellular immunity), and patients with hematologic malignancies such as chronic lymphocytic leukemia and lymphoma. In resource-rich countries, the epidemiological shift of cryptococcosis away from HIV toward transplant and other immunosuppressed populations has become pronounced as effective antiretroviral therapy (ART) has reduced advanced AIDS.
Cryptococcus gattii presents a distinctly different epidemiological profile. Historically confined to tropical and subtropical zones — Papua New Guinea, Southeast Asia, northern Australia, South America — it gained worldwide attention following an unprecedented outbreak beginning in 1999 on Vancouver Island, British Columbia, Canada, in a temperate climate. This outbreak subsequently spread to mainland British Columbia and the Pacific Northwest of the United States. Critically, C. gattii causes severe disease including large cryptococcomas in apparently immunocompetent individuals at a substantially higher rate than C. neoformans, though subtle immune defects (e.g., anti-GM-CSF antibodies) may be identified on careful investigation. C. gattii infection carries a higher neurological complication rate and worse long-term functional outcomes.
Pathophysiology
The pathogenesis of cryptococcosis begins with inhalation of desiccated yeast cells or basidiospores into the alveolar spaces. In immunocompetent hosts, alveolar macrophages engulf the organisms and, with assistance from activated CD4+ T helper 1 (Th1) cells producing interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), drive granuloma formation and eventual clearance or establishment of latent infection — a process analogous to primary tuberculosis. Reactivation of latent cryptococcal infection can occur decades later if cellular immunity subsequently becomes impaired.
In immunocompromised hosts — most critically those with advanced HIV depleting CD4 T-cells — the Th1 response is fatally weakened. The polysaccharide capsule (GXM) plays a central immunosuppressive role: it inhibits phagocytosis directly, activates complement via the alternative pathway in a non-protective manner, induces IL-10 production (a Th2-skewing, anti-inflammatory cytokine), and blocks T-cell proliferation. With the cellular immune brake removed, Cryptococcus proliferates within alveolar macrophages and subsequently disseminates hematogenously.
CNS tropism — the hallmark of severe cryptococcosis — arises from at least three converging mechanisms: (1) the CSF and brain parenchyma have inherently low complement levels, leaving the capsule's complement-evasion strategy especially effective; (2) laccase-mediated melanin synthesis uses dopamine as a substrate, and the catecholamine-rich environment of the basal ganglia and CSF provides a selective advantage; (3) the "Trojan horse" mechanism, whereby intact yeast cells sheltered inside circulating macrophages cross the blood-brain barrier through transcytosis, evading immune surveillance. Once in the subarachnoid space, yeast proliferates without effective host control, producing gelatinous masses and generating the pathological hallmarks of cryptococcal meningitis.
Elevated intracranial pressure (ICP) is the proximate cause of early mortality in cryptococcal meningitis. The mechanism is predominantly communicating hydrocephalus: massive fungal polysaccharide burden and shed capsular material obstruct CSF reabsorption at the arachnoid granulations, raising ICP often to dangerous levels (>40 cmH2O is not uncommon). This high ICP drives transtentorial and cerebellar herniation if unmanaged, causes optic nerve ischemia (vision loss), and produces the severe headache that is the most prominent presenting symptom.
Clinical Presentation
Cryptococcosis typically presents as a subacute illness evolving over 2 to 6 weeks, though the tempo can be more acute (days) in profoundly immunosuppressed patients or more indolent (months) in immunocompetent individuals with pulmonary or limited disseminated disease. The most common and prominent symptom is headache — often described as severe, progressive, and poorly responsive to analgesics — reflecting the underlying elevation in intracranial pressure. Fever and malaise are nearly universal. Nausea and vomiting occur in proportion to ICP elevation.
A critically important clinical point: the classic signs of meningeal irritation — neck stiffness (nuchal rigidity), Kernig's sign, and Brudzinski's sign — are frequently absent in HIV-infected patients with advanced immunosuppression. The blunted inflammatory response that characterizes advanced AIDS means the CSF pleocytosis is minimal, the meningeal inflammation is subdued, and the clinical picture may appear deceptively benign until ICP elevation produces its own signs: papilledema (seen on fundoscopy), sixth or seventh cranial nerve palsies (from stretching by elevated ICP), and progressive obtundation or altered mental status. The degree of altered sensorium at presentation is among the strongest predictors of short-term mortality.
Cutaneous cryptococcosis, seen primarily in disseminated disease, manifests as umbilicated papules resembling molluscum contagiosum — a well-recognized clue to systemic dissemination. Osteolytic bone lesions, prostatic infection (the prostate may serve as a reservoir for relapse), and ocular involvement (endophthalmitis, choroidal granulomas) represent less common but clinically important extrapulmonary manifestations. A careful skin examination and dilated fundoscopic evaluation are warranted in all suspected cases.
Cryptococcal Meningitis
Cryptococcal meningitis is the most feared and lethal manifestation of cryptococcosis, responsible for the overwhelming majority of disease-related mortality. The diagnosis should be considered in any immunocompromised patient — particularly those with HIV and CD4 below 100 cells/µL — presenting with headache, fever, or altered mental status, regardless of whether classic meningismus is present.
Lumbar puncture (LP) is both diagnostic and therapeutic. Opening pressure measured in the lateral decubitus position is elevated above 25 cmH2O in approximately 75% of patients with HIV-associated cryptococcal meningitis and may exceed 40 cmH2O. CSF analysis characteristically shows a mild lymphocytic pleocytosis (typically 5–50 white blood cells/µL), mildly elevated protein, and normal or low glucose; crucially, in profoundly immunosuppressed HIV patients the CSF may be nearly acellular — an ominous finding reflecting the absence of effective inflammatory response and correlating with higher fungal burden and worse prognosis. India ink preparation, in which the polysaccharide capsule creates a clear halo surrounding the dark yeast cell, is positive in 60–80% of HIV-associated cases.
The single most sensitive and specific rapid diagnostic test is the cryptococcal antigen (CrAg) assay — available as latex agglutination (LA) or lateral flow assay (LFA). Both serum and CSF CrAg demonstrate sensitivity and specificity exceeding 99% for HIV-associated cryptococcal meningitis, making them the cornerstone of diagnosis in resource-limited settings where microscopy and culture may be unavailable. CSF culture on Sabouraud dextrose agar remains the gold standard for definitive diagnosis and susceptibility testing, though results require 48–72 hours. A prozone effect — false-negative CrAg result due to antibody excess at very high antigen titers — can occasionally occur; sample dilution before repeat testing resolves this. Beta-D-glucan is unreliable for diagnosing cryptococcosis because the organism's capsule sheds polysaccharide that diverts and consumes the test reagent.
The WHO-recommended treatment protocol (2022) follows a three-phase approach. Induction therapy (2 weeks) consists of liposomal amphotericin B (AmBisome) 3–4 mg/kg/day IV plus flucytosine (5-FC) 25 mg/kg every 6 hours orally — a combination proven superior in the landmark ACTA trial. Where liposomal formulations are unavailable, conventional amphotericin B deoxycholate (0.7–1 mg/kg/day) with 5-FC is the alternative, though nephrotoxicity is substantially greater. Consolidation therapy (8 weeks) transitions to oral fluconazole 400 mg/day. Maintenance (secondary prophylaxis) continues with fluconazole 200 mg/day lifelong, or until CD4 count exceeds 200 cells/µL for at least 6 months on suppressive ART — at which point discontinuation is generally safe.
Management of elevated ICP is as critical as antifungal therapy and is the primary modifiable determinant of early survival. Therapeutic lumbar puncture — draining 20–30 mL of CSF — should be performed daily until opening pressure is consistently below 20 cmH2O. Acetazolamide is ineffective and should not be used. Corticosteroids do not reduce ICP in cryptococcal meningitis and were shown in the COAT trial to increase mortality (unlike in bacterial or tuberculous meningitis). For refractory elevated ICP unresponsive to serial LPs, lumbar drainage catheter or ventriculoperitoneal shunting may be necessary. ART initiation should be deferred 4–6 weeks after the diagnosis of cryptococcal meningitis to reduce the risk of potentially fatal immune reconstitution inflammatory syndrome (IRIS).
Pulmonary Cryptococcosis
Pulmonary cryptococcosis represents the primary portal of entry for all Cryptococcus infection and may manifest across a wide clinical spectrum — from completely asymptomatic pulmonary nodules discovered incidentally on chest imaging to severe pneumonia with acute respiratory failure. The clinical presentation depends critically on the host's immune status and the infecting species.
In immunocompetent hosts, pulmonary cryptococcosis is frequently asymptomatic or produces only mild symptoms — cough, mild dyspnea, or low-grade fever — and may self-resolve. When symptomatic, presentations include pleuritic chest pain, productive cough, and constitutional symptoms. Chest CT typically reveals single or multiple pulmonary nodules (which may mimic primary lung cancer or metastases), segmental or lobar consolidation, or less commonly a miliary pattern. Nodules may cavitate, calcify, or remain stable for extended periods. In immunocompromised patients, the clinical picture is more severe, more rapidly progressive, and more likely to reflect disseminated disease with concurrent meningitis.
C. gattii infection produces a distinctive pulmonary pattern of large granulomatous masses (cryptococcomas) — sometimes several centimeters in diameter — that may not respond to antifungal therapy and occasionally require surgical resection for definitive management. Brain cryptococcomas in C. gattii infection similarly present as space-occupying lesions on MRI, may produce focal neurological deficits, and behave differently from the diffuse meningeal inflammation typical of C. neoformans.
Diagnosis of pulmonary cryptococcosis is supported by serum or bronchoalveolar lavage (BAL) CrAg testing; BAL culture may confirm the organism. Mild-to-moderate pulmonary disease in immunocompetent patients without CNS involvement is treated with fluconazole 400 mg/day for 6–12 months. Severe pulmonary disease, respiratory compromise, or any evidence of CNS or disseminated involvement warrants the full meningitis protocol (liposomal amphotericin B plus 5-FC induction).
Diagnosis
Prompt diagnosis is essential because cryptococcal meningitis is rapidly fatal if untreated. The diagnostic approach is stratified by setting and clinical urgency. In any immunocompromised patient with compatible symptoms, serum CrAg by lateral flow assay (LFA) should be obtained immediately — it is inexpensive, point-of-care capable, requires no specialized equipment, and carries greater than 99% sensitivity and specificity for HIV-associated disseminated cryptococcosis. A positive serum CrAg mandates urgent lumbar puncture to assess for CNS involvement and measure opening pressure.
Lumbar puncture should include: opening pressure measurement in the lateral decubitus position, CSF cell count and differential, protein, glucose (with simultaneous serum glucose), India ink preparation, CrAg by LA or LFA, and fungal culture. Cryptococcal culture from CSF remains the gold standard and also provides isolates for antifungal susceptibility testing — increasingly important as fluconazole resistance is recognized in certain regions and following prolonged azole prophylaxis. Blood cultures are positive in 50–70% of HIV-associated cryptococcal meningitis cases, and urine cultures are useful — a positive urine culture indicates hematogenous dissemination and portends more severe disease.
Neuroimaging (CT or MRI) is indicated when focal neurological deficits or signs of herniation are present prior to LP, though it should not delay LP when imaging is unavailable. MRI findings in cryptococcal meningitis may include leptomeningeal enhancement, dilated perivascular (Virchow-Robin) spaces filled with gelatinous fungal masses ("soap-bubble" lesions in the basal ganglia), hydrocephalus, and in C. gattii infection, discrete ring-enhancing cryptococcomas.
WHO recommends routine CrAg serum screening of all HIV-positive individuals with CD4 counts below 100 cells/µL prior to initiating ART, because a positive screening CrAg indicates subclinical disseminated infection that will progress to meningitis without pre-emptive antifungal treatment. This strategy has been shown to reduce cryptococcal meningitis incidence and AIDS mortality when implemented systematically in high-burden settings.
Treatment
Antifungal treatment of cryptococcal meningitis follows the three-phase WHO 2022 protocol detailed in the Cryptococcal Meningitis section. Several practical aspects of drug administration and monitoring deserve emphasis. Liposomal amphotericin B (AmBisome) is preferred over conventional amphotericin B deoxycholate because of substantially reduced nephrotoxicity, infusion-related reactions, and hypokalemia, while maintaining equivalent or superior antifungal efficacy. Pre-hydration with 500–1000 mL normal saline before each infusion reduces nephrotoxicity further. Daily monitoring of serum creatinine, potassium, magnesium, and complete blood count is mandatory during induction therapy; electrolyte supplementation is typically required.
Flucytosine (5-FC) exerts synergistic fungicidal activity with amphotericin B through intracellular conversion to 5-fluorouracil — a thymidylate synthase inhibitor that impairs fungal DNA synthesis. Dosing must be adjusted for renal function (the drug is renally cleared), and bone marrow suppression (leukopenia, thrombocytopenia) is the primary toxicity, requiring weekly CBC monitoring. Flucytosine monotherapy should never be used because resistance develops rapidly.
Fluconazole is a fungistatic triazole that achieves excellent CNS penetration (CSF levels 60–80% of serum). It is the backbone of consolidation and maintenance phases. Fluconazole inhibits CYP2C9 and CYP3A4 and has numerous drug interactions (rifampin significantly reduces fluconazole levels; fluconazole increases warfarin, tacrolimus, and phenytoin levels). Emerging fluconazole resistance, particularly in patients with prior azole prophylaxis, is an increasing clinical concern; minimum inhibitory concentration (MIC) testing is warranted in treatment failures.
Salvage therapy for refractory or relapsed cryptococcal meningitis options include: high-dose fluconazole (800–1200 mg/day) combined with 5-FC; isavuconazole (broad-spectrum triazole with activity against Cryptococcus); and in investigational settings, olorofim — a first-in-class dihydroorotate dehydrogenase (DHODH) inhibitor with potent in vitro activity against Cryptococcus. The AMBITION-cm trial established that a single high-dose (10 mg/kg) infusion of liposomal amphotericin B followed by oral antifungals was non-inferior to the 1-week course for HIV-associated cryptococcal meningitis, potentially simplifying treatment and reducing hospital days in resource-limited settings.
Complications
Immune reconstitution inflammatory syndrome (IRIS) is the most feared complication of cryptococcal meningitis management in HIV-infected patients initiating ART. Cryptococcal IRIS occurs in 15–40% of patients when ART is started; it manifests as paradoxical clinical worsening — escalating headache, fever, meningeal signs, new or enlarging lymphadenopathy, new cryptococcomas on imaging — despite microbiological control with declining CrAg titers and negative cultures. The mechanism is a restored immune system "overreacting" to residual fungal antigens. In its most severe form, cryptococcal IRIS produces cerebral edema and rapid neurological deterioration that can be fatal. The COAT trial definitively demonstrated that early ART initiation (within 1–2 weeks of meningitis diagnosis) significantly increased 26-week mortality compared with deferred ART (4–6 weeks), establishing the current delayed-ART recommendation. Severe IRIS is managed with dexamethasone 0.4 mg/kg/day, tapered over 2 weeks, with careful monitoring.
Hydrocephalus — predominantly communicating in type, from obstruction of CSF reabsorption by fungal polysaccharide at arachnoid granulations — is both an acute cause of mortality and a chronic complication. Patients who survive the acute illness but develop persistent elevated ICP or progressive neurological decline may require ventriculoperitoneal (VP) shunt placement, a procedure associated with its own risks but life-saving in refractory cases. Obstructive hydrocephalus from cryptococcal masses is managed similarly.
Vision loss is a devastating complication, occurring through multiple mechanisms: optic nerve ischemia or infarction from sustained elevated ICP, direct fungal invasion of the optic nerve (cryptococcal optic neuropathy), and retinal vascular occlusion. Once vision loss occurs, it is often irreversible; aggressive ICP management is the primary preventive strategy. Bilateral sensorineural hearing loss, while less common, is similarly irreversible when it occurs. Amphotericin B nephrotoxicity can cause acute kidney injury requiring temporary or permanent renal replacement therapy in severe cases. 5-FC–related myelosuppression can cause life-threatening cytopenias requiring dose reduction or drug discontinuation.
Prognosis
Cryptococcal meningitis carries substantial mortality even with optimal antifungal therapy. In clinical trials conducted in resource-rich settings with liposomal amphotericin B plus 5-FC, 10-week mortality ranges from 20–30%. In resource-limited settings where liposomal amphotericin B and 5-FC are unavailable or unaffordable, mortality approaches 50–70% — a stark reflection of the importance of regimen quality. Observational data from sub-Saharan Africa, where most of the global burden lies, confirms that mortality remains unacceptably high without access to the full WHO-recommended induction regimen.
Independent predictors of early mortality include: altered mental status or coma at presentation, very high opening pressure on initial LP (>40 cmH2O), very high CSF fungal burden (quantitative culture colony counts), minimal CSF pleocytosis (less than 5 WBC/µL — reflecting profound immunosuppression), and the absence of 5-FC in the induction regimen. Conversely, patients who receive flucytosine-containing induction therapy, who achieve rapid CSF sterilization (negative culture at 2 weeks), and who have CD4 recovery on ART have substantially improved outcomes.
C. gattii infection carries a worse prognosis than C. neoformans in matched analyses, attributable to the higher prevalence of large cryptococcomas producing mass effect, the higher rate of neurological sequelae (focal deficits, seizures, cognitive impairment), and the longer duration of antifungal therapy typically required. In immunocompetent hosts with C. gattii pulmonary cryptococcosis without CNS involvement, outcomes are generally favorable with appropriate azole therapy, though complete radiographic resolution of pulmonary cryptococcomas may take 12–18 months. With sustained ART and secondary fluconazole prophylaxis, patients who achieve CD4 recovery above 200 cells/µL can safely discontinue maintenance therapy, and long-term survival approaches that of the broader HIV-positive population.
Prevention
The most impactful preventive strategy for HIV-associated cryptococcal meningitis is WHO-recommended serum CrAg screening of all HIV-positive individuals with CD4 counts below 100 cells/µL prior to ART initiation. When the screening CrAg is positive (indicating subclinical disseminated infection), a targeted pre-emptive treatment protocol is initiated: fluconazole 800 mg on day 1, then 400 mg/day for 2 weeks, followed by 200 mg/day consolidation — without requiring LP unless neurological symptoms are present. CrAg-positive patients should have LP if any symptoms suggest CNS involvement. This approach, validated in large African studies, substantially reduces progression to overt cryptococcal meningitis after ART initiation and has been shown to reduce overall AIDS-related mortality.
Primary antifungal prophylaxis with fluconazole 200 mg/day is recommended in high-prevalence settings (particularly sub-Saharan Africa) for all HIV-positive individuals with CD4 below 100 cells/µL, irrespective of CrAg status. In resource-rich countries, where CrAg screening is feasible and ART can be initiated promptly, the benefit-to-risk ratio of universal primary prophylaxis is less favorable (considering drug interactions, resistance selection, and cost), and CrAg-guided pre-emptive therapy is preferred over blanket prophylaxis.
Secondary prophylaxis — maintenance fluconazole 200 mg/day — is mandatory after treatment of cryptococcal meningitis to prevent relapse. Discontinuation is safe when CD4 count exceeds 200 cells/µL for at least 6 consecutive months on suppressive ART, with undetectable HIV viral load. Environmental precautions — avoiding environments with heavy pigeon droppings, using masks during soil disturbance in endemic areas — are prudent but insufficient on their own for immunocompromised individuals. No licensed vaccine against Cryptococcus is currently available, though glucuronoxylomannan-protein conjugate vaccines are in preclinical and early clinical development.
References
- Perfect JR et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2010. PMID: 20047480
- Rajasingham R et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017. PMID: 28753998
- Jarvis JN et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med. 2022. PMID: 35704487
- Day JN et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013. PMID: 23550946
- Beardsley J et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med. 2016. PMID: 27355533
- Boulware DR et al. Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. N Engl J Med. 2014. PMID: 24971531
- Rhein J et al. Prevalence of and risk factors for cryptococcal antigenemia in HIV-infected adults hospitalized for acute meningitis in Uganda. J Acquir Immune Defic Syndr. 2016. PMID: 26925590
- Lortholary O et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005. PMID: 15750393
- Bicanic T et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients. Clin Infect Dis. 2008. PMID: 18665822
- Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2016. PMID: 27208769
- Williamson PR et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol. 2017. PMID: 27830699
- Molloy SF et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018. PMID: 29757152
Connections
- Aspergillosis
- Mucormycosis
- HIV/AIDS
- Meningitis
- Infectious Disease
- Neurology
- Histoplasmosis
- Complete Blood Count
Featured Videos
